Younger Adults Less Likely to Meet Recommended Colorectal Cancer Screening Guidelines
Younger adults in the U.S. are less likely to be screened for colorectal cancer than older adults despite now being eligible for screening.
Younger adults in the U.S. are less likely to be screened for colorectal cancer than older adults despite now being eligible for screening.
Phillips-Medisize provides end-to-end manufacturing support to Exact Sciences, developers of the FDA-approved Cologuard at-home colorectal screening test.
Carolina Liquid Chemistries Corp. has launched MyPOCtest.com, an e-commerce website to help supply medical facilities with POC rapid tests.
Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50.
Read MoreGuardant Health is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer patients.
Read MoreThe study suggests that such liquid biopsies could help personalize treatment for oligometastatic colorectal cancer.
Read MoreColorectal cancer screening rates jumped by more than 1,000% when Penn researchers sent take-at-home tests to patients overdue for testing instead of the oft-standard text message reminder.
Read MoreNew research has demonstrated that a simple, cheap test can help identify who is at risk of developing colorectal cancer, aiding early diagnosis and potentially saving lives.
Read MorePhysicians identified 9 best practices for mail-in colon cancer screening campaigns, which can take the place of invasive, unpopular colonoscopies.
Read MoreA new study comparing four CRC screening alternatives found that annual colorectal cancer screening with Epi proColon was cost effective.
Read MoreOver the course of one year, the number of colorectal cancer screenings was higher for a mailed reminder plus FIT than for a mailed reminder only.
Read MoreUsing Caris Molecular Intelligence tumor profiling results, the AI-powered predictor is intended to gauge a patient’s likelihood of benefit from FOLFOX as a first-line regimen in combination with bevacizumab.
Read MoreThe aim of the consortium is to develop a blood test based on transcriptomic and epigenetic biomarkers for early detection and relapse monitoring in CRC patients.
Read MoreIn the United States, the average age at diagnosis has decreased over the past decade.
Read MoreThe research found that younger patients were more likely than older patients to have certain genetic mutations and certain subtypes of colorectal cancer.
Read MoreThe study is being carried out in collaboration with Hvidovre Hospital at the University of Copenhagen, and involves 680 subjects from the Danish national colorectal cancer screening program.
Read MoreIn a study of more than 1,000 people screened for colorectal cancer, a fecal immunochemical test from Clinical Genomics was significantly more sensitive than two leading fecal occult blood tests for detecting colorectal cancer.
Read MoreSysmex Inostics has announced new data from a real-world prospective evaluation of the OncoBeam RAS CRC test, a liquid biopsy assay for use in metastatic colorectal cancer patients.
Read More